This study tests a daily pill called lazertinib in 150 people with advanced non-small cell lung cancer that has certain EGFR mutations. Participants have not had any prior targeted therapy. The goal is to see how long the drug controls the cancer and to understand why resistance …
Phase: PHASE2 • Sponsor: Se-Hoon Lee • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC